Therapeutic Potential of Apatinib Against Colorectal Cancer by Inhibiting VEGFR2-Mediated Angiogenesis and β-Catenin Signaling

Xiaomin Cai1 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China

Bin Wei1 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China;2 Department of Oncology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huai’an223300, People's Republic of China

Lele Li1 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China

Xiaofeng Chen1 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China

https://orcid.org/0000-0001-6137-5234

Jing Yang1 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China

Xiaofei Li1 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China

Xiaozheng Jiang1 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China

Mu Lv1 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China

Mingyang Li1 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China

Yumeng Lin3 State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, People’s Republic of China

Qiang Xu3 State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, People’s Republic of China

Wenjie Guo3 State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, People’s Republic of ChinaCorrespondence[email protected]

https://orcid.org/0000-0001-8506-3905

Yanhong Gu1 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of ChinaCorrespondence[email protected]

show all

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Articles from other publishers (7)

Huafeng Jiang, Senjun Zhou & Gang Li. (2023) Novel biomarkers used for early diagnosis and tyrosine kinase inhibitors as targeted therapies in colorectal cancer. Frontiers in Pharmacology 14.
Crossref

Nikolay Shakhpazyan, Liudmila Mikhaleva, Arkady Bedzhanyan, Zarina Gioeva, Nikolay Sadykhov, Alexander Mikhalev, Dmitri Atiakshin, Igor Buchwalow, Markus Tiemann & Alexander Orekhov. (2023) Cellular and Molecular Mechanisms of the Tumor Stroma in Colorectal Cancer: Insights into Disease Progression and Therapeutic Targets. Biomedicines 11:9, pages 2361.
Crossref

Kirti K. Iyer, Nielka P. van Erp, Daniele V.F. Tauriello, Henk M.W. Verheul & Dennis Poel. (2022) Lost in translation: Revisiting the use of tyrosine kinase inhibitors in colorectal cancer. Cancer Treatment Reviews 110, pages 102466.
Crossref

Qi Feng, Donglai Wang, Peng Guo, Zibo Zhang & Jiangang Feng. (2022) Apatinib Functioned as Tumor Suppressor of Synovial Sarcoma through Regulating miR-34a-5p/HOXA13 Axis. Computational and Mathematical Methods in Medicine 2022, pages 1-15.
Crossref

Caie Li, Liping Ma, Qiongying Wang, Xuejiao Shao, Lu Guo, Jianshu Chen, Wenjuan Wang & Jing Yu. (2022) Rho kinase inhibition ameliorates vascular remodeling and blood pressure elevations in a rat model of apatinib-induced hypertension. Journal of Hypertension 40:4, pages 675-684.
Crossref

Andrés Ballesteros-Casallas, Margot Paulino, Pietro Vidossich, Carol Melo, Elizabeth Jiménez, Juan-Carlos Castillo, Jaime Portilla & Gian Pietro Miscione. (2022) Synthesis of 2,7-diarylpyrazolo [1,5-a] pyrimidine derivatives with antitumor activity. Theoretical identification of targets. European Journal of Medicinal Chemistry Reports 4, pages 100028.
Crossref

Xuetong Rong, Haiyi Liu, Hongmei Yu, Jian Zhao, Jie Wang & Yusheng Wang. (2022) Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer. Investigational New Drugs 40:2, pages 340-348.
Crossref

Therapeutic Potential of Apatinib Against Colorectal Cancer by Inhibiting VEGFR2-Mediated Angiogenesis and β-Catenin Signaling

Articles from other publishers (7)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Therapeutic Potential of Apatinib Against Colorectal Cancer by Inhibiting VEGFR2-Mediated Angiogenesis and β-Catenin Signaling

Citations (7)

Articles from other publishers (7)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date